Background: In the double-blind, phase 3 KEYNOTE-189 study (NCT02578680), pembrolizumab+pemetrexed/platinum significantly improved OS and PFS over placebo+pemetrexed/platinum as first-line therapy for nonsquamous NSCLC. Overall, the incidence and severity of AEs with pembrolizumab+pemetrexed/platinum was similar to those with placebo+pemetrexed/platinum. We report the prespecified patient-reported outcome (PRO) analyses from KEYNOTE-189. Method: 616 patients were randomized to pembrolizumab 200 mg Q3W or placebo for 2 years; all patients received pemetrexed plus 4 cycles of carboplatin/cisplatin. EORTC QLQ-C30 and QLQ-LC13 were administered at cycles 1-5, then every 3 cycles during year 1, and every 4 cycles during years 2/3. Key PROs were change from baseline to weeks 12 and 21 in the QLQ-C30 global health status (GHS)/quality of life (QoL) score and time to deterioration in composite of cough/chest pain/ dyspnea. PROs were analyzed in all treated patients who completed 1 PRO instrument (n ¼ 602). P values are nominal and 2-sided. Results: QLQ-C30 compliance was w90% at baseline and week 12 in both arms and was w76% with pembrolizumab and w64% with placebo at week 21. Mean baseline scores were 61.98 and 60.56 in the pembrolizumab and placebo arms, respectively. At weeks 12 and 21, GHS/QoL scores were stable with pembrolizumab and decreased with placebo, with significantly greater decrement with placebo at week 21 (Table) . The proportion of improved GHS/QoL was similar at week 12 (28.9% with pembrolizumab vs 26.5% with placebo) but was greater with pembrolizumab at week 21 (30.1% vs 22.5%). Median time to deterioration in composite of cough/chest pain/dyspnea was not reached (NR) with pembrolizumab (95% CI, 10.2 months-NR) vs 7.0 months (95% CI, 4.8-NR) with placebo (HR, 0.81; 95% CI, 0.60-1.09; P¼0.161). Conclusion: In KEYNOTE-189, pembrolizumab+pemetrexed/platinum maintained or improved health-related QoL over placebo+pemetrexed/ platinum. These data support use of pembrolizumab+pemetrexed/ platinum as first-line therapy for metastatic nonsquamous NSCLC. Background: PD-L1 expression on tumor cells is associated with improved clinical benefit from immunotherapies targeting the PD-1 pathway. We conducted a global, multicenter, retrospective observational study to determine real-world prevalence of tumor PD-L1 expression in patients with advanced NSCLC. Method: Patients 18 years with histologically confirmed stage IIIB/IV NSCLC and a tumor tissue block (5 years old) obtained before treatment at or after this stage were identified in 45 centers across 18 countries including 4 centers in Argentina and Colombia. PD-L1 tumor expression was evaluated at each institution using the PD-L1 IHC 22C3 pharmDx kit (Agilent, Santa Clara, CA, USA). The percentages of patients with PD-L1 tumor proportion score (TPS) 50%, TPS 1%, and TPS <1% were described overall and by relevant clinicopathologic characteristics. Results: Of 2617 patients who met inclusion criteria, 2368 (90%) had PD-L1 data (of which 266 were from Argentina and Colombia sites); 530 (22%) were TPS 50%, 1232 (52%) were TPS 1%, and 1136 (48%) were TPS <1% (Table) . The percentage of patients with PD-L1 TPS 50% and TPS 1%, respectively were: 22%/52% in Europe; 22%/53% in Asia Pacific; 21%/47% in the Americas, and 24%/55% in other countries. The prevalence of EGFR mutations (19%) and ALK alterations (3%) was consistent with prior reports in metastatic NSCLC. Among 1064 patients negative for both EGFR mutation and ALK alteration, the percentage of patients with PD-L1 TPS 50% and TPS 1%, respectively, were 27% and 53%. Conclusion: This is the largest real-world study in advanced NSCLC to date evaluating PD-L1 tumor expression using the 22C3 pharmDx kit. Testing failure rate was low despite local evaluation of PD-L1 TPS across a large number of sites. Prevalence of PD-L1 TPS 50% and TPS 1% was similar across geographic regions and broadly consistent with central testing results
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